1. Molecular epigenetic targets for liver diseases: current challenges and future prospects
    Robert Zeidler et al, 2017, Drug Discovery Today CrossRef
  2. The Notch ligand delta-like 3 promotes tumor growth and inhibits Notch signaling in lung cancer cells in mice
    San-Ming Deng et al, 2017, Biochemical and Biophysical Research Communications CrossRef
  3. Differential expression of the Notch1 receptor, and its ligands Dll1, Dll3 and Dll4 in distinct human pituitary adenoma subtypes
    Jianfu Zhang et al, 2017 CrossRef
  4. Oncogenic role of the Notch pathway in primary liver cancer
    JIE LU et al, 2016 CrossRef
  5. Delta-like 3 is silenced by HBx via histone acetylation in HBV-associated HCCs
    Hiroki Hamamoto et al, 2018, Sci Rep CrossRef
  6. Distinctive pattern of AHNAK methylation level in peripheral blood mononuclear cells and the association with HBV-related liver diseases
    Libo Sun et al, 2018, Cancer Med CrossRef
  7. Upregulated delta-like protein 3 expression is a diagnostic and prognostic marker in endometrial cancer
    Juan Wang et al, 2018, Medicine CrossRef
  8. Knockdown of Delta-like 3 restricts lipopolysaccharide-induced inflammation, migration and invasion of A2058 melanoma cells via blocking Twist1-mediated epithelial-mesenchymal transition
    Xiaojie Ding et al, 2019, Life Sciences CrossRef
  9. DLL 3 regulates the migration and invasion of small cell lung cancer by modulating Snail
    Megumi Furuta et al, 2019, Cancer Sci CrossRef
  10. null
    Arthur Zimmermann, 2016 CrossRef
  11. A functional and protein-protein interaction analysis of neuroepithelial cell transforming gene 1 in hepatocellular carcinoma
    Ke Ye et al, 2014, Tumor Biol. CrossRef
  12. Delta‐like 3 localizes to neuroendocrine cells and plays a pivotal role in gastrointestinal neuroendocrine malignancy
    Kentaro Matsuo et al, 2019, Cancer Sci CrossRef
  13. A Genome-Wide Association Study of a Biomarker of Nicotine Metabolism
    Anu Loukola et al, 2015, PLoS Genet CrossRef
  14. null
    Arthur Zimmermann, 2017 CrossRef
  15. DLL3 expression in Large Cell Neuroendocrine Carcinoma (LCNEC) and Association with Molecular Subtypes and Neuroendocrine Profile
    B.C.M. Hermans et al, 2019, Lung Cancer CrossRef
  16. The Role of DLLs in Cancer: A Novel Therapeutic Target


    Meng-Xi Xiu et al, 2020, OTT CrossRef
  17. ZYG11A serves as an oncogene in non-small cell lung cancer and influences CCNE1 expression
    Xin Wang et al, 2016, Oncotarget CrossRef
  18. Delta-like canonical Notch ligand 3 as a potential therapeutic target in malignancies: A brief overview.
    Kentaro Matsuo et al, 2021, Cancer Sci CrossRef
  19. Elevated DLL3 in stomach cancer by tumor-associated macrophages enhances cancer-cell proliferation and cytokine secretion of macrophages
    Jian-Bin Ye et al, 2021 CrossRef
  20. DLL3 expression and methylation are associated with lower-grade glioma immune microenvironment and prognosis
    Humaira Noor et al, 2022, Genomics CrossRef
  21. Methylation‑associated inactivation of JPH3 and its effect on prognosis and cell biological function in HCC
    Yi Huang et al, 2022, Mol Med Rep CrossRef
  22. Diagnostic and prognostic value of STAP1 and AHNAK methylation in peripheral blood immune cells for HBV-related hepatopathy
    Libo Sun et al, 2023, Front. Immunol. CrossRef
  23. Identification of DLL3-related genes affecting the prognosis of patients with colon adenocarcinoma
    Jinyu Xiang et al, 2023, Front. Genet. CrossRef
  24. Advances in new targets for immunotherapy of small cell lung cancer
    Zitong Zheng et al, 2023, Thoracic Cancer CrossRef
  25. Methylation Patterns and Chromatin Accessibility in Neuroendocrine Lung Cancer
    Elsa Arbajian et al, 2020, Cancers CrossRef
  26. DLL3 as a Potential Diagnostic and Therapeutic Target in Neuroendocrine Neoplasms: A Narrative Review
    Annarita Peddio et al, 2024, Critical Reviews in Oncology/Hematology CrossRef